Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Running, not enrolling · Phase 3

Conditions studied: Moderate-to-Severe Atopic Dermatitis

In brief

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Key facts

Study ID

NCT03989206

Run by

Galderma R&D

People needed

1700

Starts

2019-12-30

Expected to finish

2026-08-31

Last updated by the study team

2024-10-30

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Galderma Investigational Site 8893 — Birmingham, Alabama, United States
• Galderma Investigational Site 8866 — Guntersville, Alabama, United States
• Galderma Investigational Site 8808 — Scottsdale, Arizona, United States
• Galderma Investigational Site 8873 — Scottsdale, Arizona, United States
• Galderma Investigational Site 8447 — Fort Smith, Arkansas, United States
• Galderma Investigational Site 8880 — North Little Rock, Arkansas, United States
• Galderma Investigational Site 8831 — Anaheim, California, United States
• Galderma Investigational Site 8906 — Bell Gardens, California, United States
• Galderma Investigational Site 8456 — Beverly Hills, California, United States
• Galderma Investigational Site 8578 — Cerritos, California, United States
• Galderma Investigational Site 8577 — Encinitas, California, United States
• Galderma Investigational Site 8636 — Fountain Valley, California, United States
• Galderma Investigational Site 8224 — Fremont, California, United States
• Galderma Investigational Site 8791 — Fresno, California, United States
• Galderma Investigational Site 8888 — Fullerton, California, United States
• Galderma Investigational Site 8845 — Huntington Beach, California, United States
• Galderma Investigational Site 8833 — Inglewood, California, United States
• Galderma Investigational Site 8686 — Lomita, California, United States
• Galderma Investigational Site 8674 — Los Angeles, California, United States
• Galderma Investigational Site 8683 — Los Angeles, California, United States
• Galderma Investigational Site 8813 — Los Angeles, California, United States
• Galderma Investigational Site 8907 — Newport Beach, California, United States
• Galderma Investigational Site 8799 — Ontario, California, United States
• Galderma Investigational Site 8745 — Pasadena, California, United States
• Galderma Investigational Site 8749 — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.